Cedars-Sinai researchers find Parkinson's disease wearable tracker useful to tailor treatment

The FDA approved the Personal KinetiGraph in late 2014. The wrist-worn device tracks the movements of Parkinson's disease patients every two minutes over anywhere from 6 to 10 days. After the approval, Cedars-Sinai researchers started a 60-patient clinical trial to demonstrate the device's effectiveness. In preliminary results, they have found that the device is useful in enabling a more objective measurement of symptoms--thereby enabling physicians to better tailor medications. "It's virtually impossible to make a well-informed treatment plan based on how patients feel they have been doing in the last three months because often they don't remember," said Dr. Michele Tagliati, director of the Movement Disorders Program in the Department of Neurology at Cedars-Sinai, in a statement. "The PKG device provides a quantitative way to monitor and understand the fluctuations of movements in our patients when they are not in the office." More

Suggested Articles

Smith+Nephew is contracting with the U.K. government to build a new ventilator specifically designed for large-scale production.

NantWorks’ ImmunityBio has begun a supercomputing collaboration with Microsoft to map out the spike protein of the novel coronavirus.

President Emmanuel Ligner talks about finalizing a multibillion-dollar deal while adjusting and responding to the global COVID-19 crisis.